CircSMEK1 Suppresses HCC via the hnRNPK‐IGF2‐AKT Axis: A Diagnostic Biomarker and Therapeutic Target
Advanced Science · 2025-12 · 12 (48)
DOI: 10.1002/advs.202505267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 17.10.2025. Verfasst von Peilan Guo und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, China Agricultural University, Beijing, 100193, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Proto-Oncogene Proteins c-akt, Heterogeneous-Nuclear Ribonucleoprotein K. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical University of Bialystok, Poland, 2115 Talent Development Program of China Agricultural University.
Abstract (Originalsprache)
The mechanism underlying metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC) is elusive, and whether circRNA can serve as biomarker or therapeutic target for MASH/HCC needs to be systematically explored. Integrative transcriptomic analysis of circRNA from MASH and HCC were performed. Multi‐cohort analyses of serum and tissues from MASH and HCC patients ( n = 206) were conducted. Mechanisms are explored via RNA‐protein interaction assays, CRISPR‐mediated knockdown, and xenograft/PiggyBac‐mediated mice models. circSMEK1 is significantly decreased in MASH/HCC tissues and serum, correlating with tumor size, vascular invasion, and overall survival. Mechanistically, nuclear circSMEK1 binds hnRNPK, promoting its ubiquitin‐mediated degradation, suppressing IGF2 transcription and PI3K/AKT signaling. Loss of circSMEK1 elevated autocrine IGF2 in HCC promoting tumor growth, also activated AKT in cancer‐associated fibroblasts through paracrine, fostering an immunosuppressive microenvironment. SF3B4 overexpression drove circSMEK1 depletion in HCC. In murine models, circSMEK1 restoration inhibited tumor growth and metastasis. circSMEK1 is a tumor‐suppressor in MASH/HCC through the hnRNPK‐IGF2‐AKT axis. The serum level of circSMEK1 has non‐invasive diagnostic value for HCC (AUC = 0.790), as well as potential diagnostic utility for early HCC or high‐risk MASH, owing to its key role in bridging MASH to HCC progression. Restoring of circSMEK1, alone or combined with IGF2 inhibitors, proposing a novel therapeutic strategy for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Animal Biotech Breeding, College of Biological Sciences, China Agricultural University, Beijing, 100193, China.
- Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong, 250021, China.
- Yantai Yuhuangding Hospital Affiliated to Qingdao University, Shandong, 264000, China.
- Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, 37801, Poland.
- Department of Physiology, Institute of Biomedicine, University of Turku, Turku, 20520, Finland.
- School of Life Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
ORCID-Profile: Peilan Guo, Xiangdong Li
Förderung
- National Natural Science Foundation of China
- Medical University of Bialystok, Poland
- 2115 Talent Development Program of China Agricultural University
Zitieren
APA
Guo, P., Jia, X., Wang, S., Li, X., Liu, Y., Lin, L., Wang, Z., Liu, F., Wolczynski, S., Rahman, N., Gao, J., Du, X., Tsang, S. Y., Liu, J., Song, W., & Li, X. (2025). CircSMEK1 Suppresses HCC via the hnRNPK‐IGF2‐AKT Axis: A Diagnostic Biomarker and Therapeutic Target. Advanced Science, 12(48). https://doi.org/10.1002/advs.202505267
Vancouver
Guo P, Jia X, Wang S, Li X, Liu Y, Lin L, et al. CircSMEK1 Suppresses HCC via the hnRNPK‐IGF2‐AKT Axis: A Diagnostic Biomarker and Therapeutic Target. Advanced Science. 2025;12(48). doi:10.1002/advs.202505267
BibTeX
@article{Guo2025,
author = {Guo, Peilan and Jia, Xiaomeng and Wang, Shenghong and Li, Xinyu and Liu, Yajing and Lin, Lisen and Wang, Zhengkun and Liu, Fujun and Wolczynski, Slawomir and Rahman, Nafis and Gao, Jie and Du, Xuguang and Tsang, Suk-Ying and Liu, Jiali and Song, Wei and Li, Xiangdong},
title = {CircSMEK1 Suppresses HCC via the hnRNPK‐IGF2‐AKT Axis: A Diagnostic Biomarker and Therapeutic Target},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {48},
doi = {10.1002/advs.202505267}
}
EUVIMED